Contributions
Abstract: EP1386
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - MS symptoms
Introduction: the language, voice, speech, breathing and swallowing disorders represents a group of pathologies few addressed in clinical multiple sclerosis (MS) studies.
Aim: To analyze speech disorders profile in a group of patients MS who are admitted to a neurorehabilitation unit (NRU) and its relationship with clinical parameters.
Methods: retrospective analysis of medical records of MS patients admitted into the NRU between 2010-2018. Were recorded: age, gender, EDSS scale, age at the beginning of the MS, years of MS evolution, presence and type of language, voice, speech, breathing and swallowing disorder and Functional Independence Measure (FIM) scale. A descriptive and correlational statistical analysis was performed using SPSS 19.
Results: of 172 MS admissions into the NRU, 64 were referred by the neurologist to speech therapist. 11 of them did not present speech pathology and 53 (30,81 %) had speech pathology. 60.4%, 35.8% and 3.8% were RR, SP and PP respectively; 67.9% women; average age: 46 ± 10 years, EDSS: 5.5 ± 1.5, years of evolution: 13 ± 8 years, age at the beginning of MS: 32 ± 10 years, FIM: 89.5 ± 22.9. Of the 53 evaluations performed (41 patients) the most frequent pathology was language disorder in 68%, followed by swallowing disorders (56.6%). The most frequent type of language disorder was the decrease in verbal fluency (86%). 86, 8% of evaluations showed more than one disorder. We found correlation between the total number of disorder in each patient with EDSS (r: 0.34, p = 0.046). We did not find correlation with years of evolution and FIM (r: -0.15, r: 0.14 respectively).
Conclusion: Given the high frequency of speech disorders, will be necessary to perform standardized evaluations to offer a comprehensive treatment to MS patients.
Disclosure: MLS received honoraria for attendance at Congresses from Biogen Idec. and Novartis. He also received honoraria as a speaker at Roche. BAS received honoraria for attendance at congresses, speaker and educational activities from Biogen Idec; Novartis; Genzyme, Merck, Teva and Bayer. FC received fees for consultancy and Advisory Board membership and fees for travel, academic conferences and research projects from Genzyme, Novartis, Merck, Ivax, Roche and Biogen Idec. AM nothing to disclose
Abstract: EP1386
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - MS symptoms
Introduction: the language, voice, speech, breathing and swallowing disorders represents a group of pathologies few addressed in clinical multiple sclerosis (MS) studies.
Aim: To analyze speech disorders profile in a group of patients MS who are admitted to a neurorehabilitation unit (NRU) and its relationship with clinical parameters.
Methods: retrospective analysis of medical records of MS patients admitted into the NRU between 2010-2018. Were recorded: age, gender, EDSS scale, age at the beginning of the MS, years of MS evolution, presence and type of language, voice, speech, breathing and swallowing disorder and Functional Independence Measure (FIM) scale. A descriptive and correlational statistical analysis was performed using SPSS 19.
Results: of 172 MS admissions into the NRU, 64 were referred by the neurologist to speech therapist. 11 of them did not present speech pathology and 53 (30,81 %) had speech pathology. 60.4%, 35.8% and 3.8% were RR, SP and PP respectively; 67.9% women; average age: 46 ± 10 years, EDSS: 5.5 ± 1.5, years of evolution: 13 ± 8 years, age at the beginning of MS: 32 ± 10 years, FIM: 89.5 ± 22.9. Of the 53 evaluations performed (41 patients) the most frequent pathology was language disorder in 68%, followed by swallowing disorders (56.6%). The most frequent type of language disorder was the decrease in verbal fluency (86%). 86, 8% of evaluations showed more than one disorder. We found correlation between the total number of disorder in each patient with EDSS (r: 0.34, p = 0.046). We did not find correlation with years of evolution and FIM (r: -0.15, r: 0.14 respectively).
Conclusion: Given the high frequency of speech disorders, will be necessary to perform standardized evaluations to offer a comprehensive treatment to MS patients.
Disclosure: MLS received honoraria for attendance at Congresses from Biogen Idec. and Novartis. He also received honoraria as a speaker at Roche. BAS received honoraria for attendance at congresses, speaker and educational activities from Biogen Idec; Novartis; Genzyme, Merck, Teva and Bayer. FC received fees for consultancy and Advisory Board membership and fees for travel, academic conferences and research projects from Genzyme, Novartis, Merck, Ivax, Roche and Biogen Idec. AM nothing to disclose